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We sought to establish the prevalence of lithium-induced
end-stage renal disease in two regions of Sweden with 2.7
million inhabitants corresponding to about 30% of the
Swedish population. Eighteen patients with lithium-induced
end-stage renal disease were identified among the 3369
patients in the general lithium-treated population,
representing a sixfold increase in prevalence compared with
the general population for renal replacement therapy.
All lithium-treated patients were older than 46 years at
end-stage renal disease with a mean lithium treatment time
of 23 years with ten patients having discontinued lithium
treatment an average of 10 years before the start of renal
replacement therapy. The prevalence of chronic kidney
disease (defined as plasma creatinine over 150lmol/l) in the
general lithium-treated population was about 1.2%
(excluding patients on renal replacement therapy).
Compared with lithium-treated patients without renal failure,
those with chronic kidney disease were older and most were
men but, as groups, their mean serum lithium levels and
psychiatric diagnoses did not differ. We found that end-stage
renal disease is an uncommon but not rare consequence of
long-term lithium treatment and is more prevalent than
previously thought. Time on lithium was the only identified
risk factor in this study, suggesting that regular monitoring of
renal function in these patients is mandatory.
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The toxicity of lithium and its diuretic action were well
known to the early investigators of its beneficial effects in
affective disorders.1,2 Early lithium studies concluded that
lithium-induced polyuria was reversible.2 In 1977, the risk of
irreversible lithium-induced kidney damage became an
international concern, thanks to a landmark Danish kidney
biopsy study3 whose findings were confirmed by Aurell et al.
1981.4 The concept of lithium nephropathy was defined in
the same year5 and includes structural tubular damage with
interstitial fibrosis in the presence of no or minor glomerular
damage. With this definition severe glomerular insufficiency
or even end-stage renal disease (ESRD) was considered an
unlikely event. Until 2000, only three cases of lithium-
induced ESRD were known in the world literature.6–8
However, the main result of studies by Bendz et al.9–11
during the 1980s was a high prevalence of apparently
irreversible tubular and glomerular damage in patients who
had been treated with lithium for 15 years or more (‘long-
term treatment’). In addition, they showed that the damage
was progressive. Therefore, it is to be expected that some
lithium-treated patients will reach ESRD after long-time
treatment. Accordingly, two recent reports from the United
States and France added further cases of lithium-induced
ESRD and reported a 2–7% prevalence of this serious adverse
effect of lithium treatment in ESRD populations.12,13 More-
over, in addition to the tubular and interstitial changes,
glomerular changes compatible with focal glomerular
sclerosis were not infrequently seen in renal biopsies from
patients with clinical lithium nephropathy. These patients
also had increased protein excretion in the urine, sometimes
even in the nephrotic range raising the suspicion of a ‘direct
glomerular’ (that is, podocyte) toxicity of lithium.12
Nevertheless, the prevailing belief among psychiatrists
today seems to be that lithium-induced uremia is practically
nonexistent. In a recent publication—primarily intended for
patients and their relatives—by one of the world’s most
prominent and influential lithium researchers, the problem is
not even mentioned.14
Thus, the prevalence of lithium-induced uremia remained
to be assessed in an epidemiological study of patients on
renal replacement therapy (RRT). The Swedish Registry for
Active Treatment of Uremia (SRAU)15 offered a possibility to
do this. In addition, information on the prevalence of
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chronic kidney disease (CKD) among lithium-treated
patients can provide an indication of the number of potential
future candidates for RRT.
The aims of this study were to investigate the following:
1. The prevalence of patients with lithium-induced ESRD
among all RRT patients in two defined regions in Sweden.
2. The prevalence of lithium-induced ESRD among all
lithium-treated patients in these regions.
3. The prevalence of CKD (defined as plasma creatinine
4150 mmol/l) among all lithium-treated patients in the
two regions.
RESULTS
Patients with lithium-induced ESRD treated with RRT in the
two regions
Twenty-seven RRT patients declared previous or present
lithium treatment, four of them erroneously. Another three
lithium-treated patients had ESRD not caused by lithium,
and two lithium-treated patients had started RRT after the
prevalence date. Thus, 18 patients were identified to have
ESRD caused by lithium alone or as a main etiological factor.
Individual data are presented in Table 1.
In eight patients, lithium treatment began during the
second half of the 1960s, in nine patients during the first half
of the 1970s, and in one it began in 1980. Although regular
monitoring of plasma creatinine levels did not become part
of lithium safety routines until the end of the 1970s, we were
in most cases able to trace the slow increase of plasma
creatinine from normal to ESRD.
The male/female proportion among the lithium-RRT
patients (39/61%) did not differ from that in the general
lithium-treated population (41/59%). The women were older
than the men at start of lithium-treatment and at start
of RRT.
All lithium-RRT patients had been treated with lithium
for at least 12 years, 16 of them (89%) X15 years. In 10
patients, lithium treatment was discontinued 3–16 years
before the start of RRT. The residual renal function at the
time of discontinuation of lithium varied considerably. Two
female patients developed ESRD, despite discontinuation at
plasma creatinine levels below 100 mmol/l. Both patients had
lower serum creatinine levels (o65 mmol/l) at start of lithium
treatment and there was a gradual increase of the serum
creatinine levels during treatment.
There was only one patient with a history of clinically
evident lithium intoxication. He suffered from confusion,
disorientation, tremor, and muscular rigidity for several
weeks during the third year of treatment. The lithium dose at
the time of intoxication was 48mmol/24 h, and two
consecutive serum lithium concentrations within 1 month
were 2.2 and 1.7mmol/l.
The prevalence of long-term lithium treatment
We received information on treatment duration from 12
lithium clinics comprising 27% of the lithium-treated































1 M 52 46 26 Lithium continued Not applicable 0 — SCH
2 M 54 54 33 Lithium continued Not applicable 0 — SCH
3 M 63 54 426 Lithium continued Not applicable 1 + BP
4 M 64 59 16 16.2 155 0 — CP
5 M 67 65 25 9.3 190 0 + BP
6 M 65 65 31 Lithium continued Not applicable 0 + BP
7 M 64 62 28 Lithium continued Not applicable 0 — CP
8 F 64 57 21 6.6 219 0 + BP
9 F 56 51 12 7.0 142 0 + BP
10 F 68 62 16 2.8 98 0 — UP
11 F 67 64 17 9.6 144 0 + SCH
12 F 76 74 35 Lithium continued Not applicable 0 — CP
13 F 78 73 20 10 274 0 — BP
14 F 76 73 20 8.5 140 0 — BP
15 F 60 58 13 16.1 94 0 — BP
16 F 61 58 20 Lithium continued Not applicable 0 + BP
17 F 67 67 35 Lithium continued Not applicable 0 — BP
18 F 67 65 18 14.5 125 0 — SCH
All 7/11 65 (7) 62 (8) 23 (7) 10.1 (4) 158 (55) 1 7+/11 10/1/3/4
M 7 61 (6) 58 (7) 26 (6) 12.7 (5) 173 (25) 1 3+/4 3/0/2/2
F 11 67 (7) 64 (8) 21 (8) 9.4 (4) 155 (62) 0 4+/7 7/1/1/2
Abbreviations: BP, bipolar disorder; CP, cycloid psychosis; SCH, schizophrenia; UP, unipolar disorder.
aThe assessment of the causal association between the lithium treatment and ESRD was based on the following operational definitions: (1) lithium is the only possible
etiological factor (patients nos. 1–14); (2) lithium is the main etiological factor (patients nos. 15–18).
bRRT, renal replacement therapy (dialysis or transplantation).
cRenal biopsy findings with structural tubular and interstitial changes and fibrosis compatible with lithium nephropathy.
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patients in the two regions. Thirty-eight percent of the
patients had been on lithium for 15 years or more, 60% for
less than 15 years, while the information was either uncertain
or missing in only 2% of the patients. We therefore estimate
that the prevalence of long-term lithium treatment in the
general lithium population was 39%.
The prevalence of RRT patients with lithium-induced ESRD
There was no difference in RRT prevalence between the two
study regions neither in the general population nor in the
lithium-treated population. The prevalence of patients with
lithium-induced ESRD in the RRT population was 8.1%
(95% confidence interval 4.4–11.8%), and the prevalence of
RRT patients in the lithium-treated population was 5.3%
(95% CI 2.8–7.8%), which means sixfold increases compared
with the general population. The RRT prevalence in the
estimated group of long-term lithium patients was 2.5 times
higher than that of the entire lithium-treated population. We
could not calculate standard morbidity rate as information
on age and sex was unavailable in the long-term group
(Table 2).
Chronic kidney disease in the lithium-treated population
The prevalence of lithium treatment in the general popula-
tion was 1.3% (Table 2), and 12% of these patients had
plasma creatinine levels4150 mmol/l (41 patients, excluding
patients on RRT). Compared with all lithium-treated
patients, those with nephropathy were older, and the sex
ratio was reversed, although there was no difference in mean
serum lithium levels or psychiatric diagnoses (Table 3).
Observed and expected lithium-induced ESRD in different
age groups
Compared with the general population ESRD was three times
more common among lithium-treated males and almost
six times more common among lithium-treated females
(Table 4). All lithium-RRT patients were older than 40 years
when RRT was started or when they discontinued lithium.
Standard morbidity rate for the two genders jointly was 433
(95% CI 265–672; Po0.001).
DISCUSSION
This is the first prevalence study of terminal lithium
nephropathy in a large cohort of RRT patients from a
general population of close to 3 million inhabitants in a
country with good access to psychiatric and nephrology
service and RRT facilities. The main finding of our study was
the identification of 18 cases of lithium-induced ESRD
resulting in a clearly increased morbidity rate.
The observed 8.1% prevalence of lithium-induced ESRD
in RRT patients corresponds to close to 1 in 100 patients in
the Swedish RRT population. This contrasts with the results
of the only comparable study by Presne et al.13 who found a
2% prevalence of lithium-treated patients among dialysis
patients in France. The prevalence they reported is clearly an
underestimation, as it included only questionnaire-respond-
ing centers with a 56% response rate and, in contrast to the
present study, did not include transplanted patients.
Table 2 | The various populations and the prevalences within them
The populations Ska˚ne region Va¨stra Go¨taland region Both regions
1 General population 31/03/2005 1,162,134 1,522,023 2,684,157
2 RRT population 994 1208 2202
3 Lithium-induced RRT patients (see also Table 1) 7 11 18
4 Lithium-treated population 1289 2080 3369
5 Patients treated with lithium X15 years (estimate) 502 811 1313
6 Lithium patients with P-creatinine 4150mmol/l 16 25 41
The prevalences % % %
1 RRT patients in the general population 0.9 0.8 0.8
2 RRT patients in the lithium-treated population 5.4 5.3 5.3
3 Lithium-induced ESRD patients in the RRT population 6.9 9.0 8.1
4 RRT in patients on lithium X15 years (estimate) 13.9 11.1 12.2
5 Lithium-treated patients in the general population 1.1 1.4 1.3
6 P-creatinine 4150mmol/l in the lithium-treated population 12.4 12.0 12.2
Abbreviations: ESRD, end-stage renal disease; RRT, renal replacement therapy.
Table 3 | Demographic and clinical data for all lithium
patients and for those with plasma creatinine
4150lmol/l (CKD)
All patients CKD patients
n=3369 n=41
Mean plasma lithium concentration,












Mean age, years (s.d.; median; range) 56 (15; 56; 18–99) 68 (11; 66;
48–94)
Sex M/F (%) 41/59 56/44
ICD 10 clinical diagnoses (%)
BP/UP/CP/SCH/MISC
60/20/16/2/2 61/12/22/5/0
Abbreviations: BP, bipolar psychosis; CKD, chronic kidney disease; CP, cycloid and
schizoaffective psychosis; MISC, miscellaneous; SCH, schizophrenia, schizotypal,
delusional; UP, unipolar psychosis.
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We took great care to ascertain the completeness of data on
the prevalence of RRT patients with lithium-induced ESRD.
We believe that the prevalence is representative of the
prevalence of lithium-induced ESRD, as the proportion of
ESRD patients not treated by RRT in Sweden is estimated to
be less than 5% based on previous regional surveys (SRAU,
unpublished data). In addition, the sixfold increase of RRT
prevalence was identical between the RRT population and the
lithium population, indicating that both our population data
are sufficiently complete.
The medical records were reviewed by three of the
authors, and only patients who fulfilled the established
criteria were included as lithium-induced ESRD. Nevertheless,
some RRT patients with previous lithium treatment may have
escaped identification. In contrast, it is highly unlikely that
patients with non-lithium-induced ESRD were included
among the patients judged to have lithium-induced ESRD.
It may be argued that RRT patients who had discontinued
lithium before RRT should not be considered members of the
current lithium-induced ESRD population. We concluded
from the case histories that these patients would have
continued with lithium, had it not been for their renal
insufficiency. Their exclusion from the lithium-induced
ESRD population would misleadingly reduce the size of the
problem.
In Sweden, renal biopsies are not routinely performed to
establish the diagnosis of lithium nephropathy but may be
performed to confirm the diagnosis or to evaluate the
extent of irreversible structural changes. In five reexamined
cases with renal biopsies performed before ESRD, the
findings were compatible with the findings as previously
described by Aurell et al.4 and more recently by Markowitz
et al.12 with distinct chronic tubulointerstitial inflammation,
dilated tubules, and including microcysts in three cases
in addition to glomerulosclerosis. The other two patients
had distinct lithium nephropathy findings in their renal
biopsies. In three cases, the biopsies were performed more
than 6 years after discontinuation of lithium treatment.
In two additional but not reexamined cases, the originally
reported findings were compatible with the same criteria. The
biopsy findings clearly support the diagnosis of lithium
nephropathy.
In this study, 10 out of 18 patients progressed to ESRD in
the course of several years, despite having discontinued
lithium treatment. Progress to ESRD after discontinuation of
lithium treatment has been observed by others as early as
1979.6 More recently, Markowitz et al.12 found among 6514
kidney biopsies 24 (3.7%) lithium-treated patients, all of
them with CKD and with a renal histopathology compatible
with lithium nephropathy. There were follow-up data from
3 months to 11 years on 19 patients, 18 of whom had
discontinued lithium at the time of biopsy. Eight of them
progressed to ESRD. The plasma creatinine level at the time of
biopsy was a predictor for ESRD. Only one out of 10 patients
with plasma creatinine levels o2.5mg/dl (E220mmol/l)
progressed to ESRD after 11 years, in three of them plasma
creatinine declined, whereas seven out of nine patients with
plasma creatinine levels 42.5mg/dl progressed to ESRD.
Lepkifker et al.16 reported similar findings in a retrospective
study of 114 lithium-treated patients. In 15 of 24 patients
(21%) whose renal function gradually deteriorated, dose
reduction or discontinuation of lithium resulted in stabiliza-
tion of plasma creatinine levels. In the remaining nine patients
renal function worsened in spite of lithium discontinuation.
Similarly, Presne et al.13 reported progress to ESRD in three
patients within 2–13 years after discontinuation of lithium.
In the lithium-treated population, we ascertained the
number of patients (3369) through personal contact with all
psychiatric clinics in the regions. All had designated registers
that covered their lithium-treated patients. In addition, we
contacted all private psychiatrists who were registered at the
public health-care authorities. The reported prevalence of
lithium-treated patients should therefore be close to the true
prevalence.
As regular measurements of plasma creatinine levels are
part of the current follow-up routines, we were able to assess
Table 4 | Absolute numbers of individuals; observed and expected cases of ESRD in the lithium population; by sex and age
Males Females



























0–19 320,233 20 5 0 0.0003 303,828 13 3 0 0.0001
20–24 80,509 18 26 0 0.0058 78,816 8 21 0 0.0021
25–34 179,605 74 119 0 0.0490 173,898 51 134 0 0.0393
35–44 191,956 176 216 0 0.1980 184,662 121 281 0 0.1841
45–54 173,672 251 293 2 0.4235 170,780 152 437 0 0.3889
55–64 172,598 356 380 3 0.7838 170,326 175 535 4 0.5497
65–74 107,585 266 216 2 0.5341 118,311 179 340 4 0.5144
75–84 74,729 202 94 0 0.2541 102,546 103 197 3 0.1979
85–99 22,650 23 18 0 0.0183 48,649 14 46 0 0.0132
Missing 3 0 Unknown 5 0 Unknown
Total 1,323,537 1386 1370 7 2.2669 1,351,816 816 1999 11 1.8897
Abbreviation: ESRD, end-stage renal disease.
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the prevalence of patients with CKD. We defined CKD in this
patient population by a routine serum creatinine level of
4150 mmol/l obtained at a scheduled outpatient follow-up
visit. Our conservative definition of CKD, P-creatinine
4150 mmol/l, indicates a significant impairment of renal
function and practically eliminates the bias of temporary
renal function alterations.
Our data do not permit conclusions about risk factors for
ESRD, except lithium treatment time. Sixteen (89%) out of
18 lithium patients on RRT had been treated long-term and
none for less than 12 years. Among CKD patients, an
estimated 90% had been on lithium for 15 years or more.
Still, the majority of patients on lithium treatment have
normal plasma creatinine levels even after many years on
lithium and do not progress to ESRD.11 Similarly, we cannot
say which is the safe level of renal function for continuation
or discontinuation of lithium treatment. Lithium intoxica-
tion was not a risk factor because only one patient had a
history of lithium intoxication. The distribution of gender
and of psychiatric diagnoses corresponds with other
contemporary studies on lithium patients.17–19 The indivi-
dual factors that determine the initiation of irreversible
nephropathy remain to be explored.
Several of the patients in our study had been exposed to
high lithium doses and high serum lithium levels during the
1960s and 1970s. Standard (as opposed to standardized)
serum lithium levels at the time was 0.8–1.2mmol/l.20
According to notes in the charts, serum lithium levels as
high as 1.3mmol/l were considered ‘acceptable’. The
nephrotoxic effect of lithium was obvious in some of these
future ESRD patients with a pronounced polyuria already
after a few years on lithium. It was not until the
pharmacokinetics of lithium became the foundation of
standardized serum lithium for the monitoring of treat-
ment,21 and the irreversibility of lithium nephropathy
became common knowledge3 that scientifically based safety
routines gradually developed. They included lower and
individualized serum lithium levels22,23 resulting eventually
in the average 0.59mmol/l serum lithium level of our current
lithium-treated population.
There are limitations to the study. The identification
of lithium-induced ESRD patients was to some extent based
on the recollection by RRT patients of previous lithium-
treatment and on data from medical records. The
diagnosis was established from clinical data, and renal biopsy
was available in only seven patients. To mitigate these
limitations, we applied stringent criteria for the identification
of patients with lithium-induced ESRD on RRT. This
is a cross-sectional point-prevalence study reflecting the
therapeutic practice during the foregoing decades. Most
patients started their treatment during an era when neither
the serum levels of lithium nor renal function were
monitored according to the modern standards that may
limit the predictive power of the results. It remains, however,
to be seen whether today’s use of lithium, including lower
and individualized dosages will diminish the risk for ESRD.
Our finding of CKD prevalence 12.2% in the general lithium
population indicates that this may not be the case.
In conclusion, lithium-induced ESRD exists and is a
serious long-term side effect of lithium treatment and more
prevalent than previously thought. The time on lithium
treatment is a major risk factor and development of ESRD is
not uncommon (41%) among long-term lithium patients.
The risk of renal failure as a consequence of long-term
treatment may persist even after lithium discontinuation.
Lithium is a very important and widely used therapeutic
agent for bipolar disorders, and as the number of patients on
long-term treatment is increasing more patients may be at
risk of nephropathy. Also, the risk factors for progression of
CKD despite discontinuation of lithium treatment are yet to
be defined. Regular monitoring of renal function remains
mandatory.
PATIENTS AND METHODS
The study began on 1 January 2005 and the inclusion of RRT
patients was on 31 March 2005. This is the prevalence date.
The Swedish Registry for Active Treatment of Uremia
Data since the 1960s on patients on RRT performed as dialysis or
renal transplantation have been collected in a national registry in
Sweden, SRAU.15 All patients on RRT should be reported to the
registry and the coverage of the ESRD population in Sweden is
almost 100%. Patients in the registry are followed throughout the
life. At the prevalence date 31 March 2005, there were 7266 RRT
patients in Sweden, giving a prevalence of 802 patients p.m.p.
Study populations
Two regions in Sweden were selected for this study, Ska˚ne and
Va¨stra Go¨taland. At the prevalence day, these two regions comprised
29.8% of the total population in Sweden (9,014,921 inhabitants),
each including two fairly large urban areas, several smaller cities,
and rural areas. Two study populations were identified. The first
population consisted of prevalent RRT patients with lithium-
induced ESRD. This was a cross-sectional study and only
patients alive on treatment were included. Among the 2202 RRT
patients in these regions, 49% were on dialysis and 51% had a renal
transplant. A second population was made up of patients treated
with lithium and with CKD, defined as serum creatinine levels
4150 mmol/l.
Lithium-induced ESRD among RRT patients—the first
population
The SRAU data were used to identify patients on RRTat the different
units in the two regions. They were interviewed about previous or
present lithium treatment. Patients with an alleged history of
lithium treatment had their medical records scrutinized by the study
group, evaluating the cause of ESRD, the psychotropic treatment,
and the ICD 10 chart diagnosis on which the lithium treatment was
based. The diagnosis of lithium nephropathy as cause of ESRD was
based on the following criteria:
K confirmed history of lithium treatment;
K absence of other renal diagnosis and post-renal obstruction;
K positive history of symptoms of diabetes insipidus;
K renal biopsy findings—when available—of tubular and inter-
stitial changes compatible with lithium nephropathy;
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K no evidence of potentially toxic drug treatment before lithium
treatment;
K no evidence of hypertension, renal disease, or dysfunction before
lithium treatment;
K progressive increase of serum creatinine levels or decrease of
glomerular filtration rate over years;
On the basis of these criteria, patients with a confirmed history
of lithium exposure were diagnosed as
K lithium nephropathy is the only cause for ESRD—all criteria;
K fulfilled lithium nephropathy is the main cause for ESRD—all
criteria fulfilled but occurrence of concomitant disease after start
of lithium treatment;
K lithium nephropathy is only a contributing cause for ESRD—
criteria not fulfilled
Only data from patients in the two first categories were included
in the analysis of data.
Renal biopsy. Renal biopsy was performed in seven patients as
indicated in Table 1. Five cases were reexamined, whereas in two
cases the biopsies could not be retrieved. The biopsies were
performed when glomerular filtration rate was in the range
30–50ml/min, and in three patients more than 6 years after
discontinuation of lithium treatment.
CKD among lithium-treated patients—the second population
To establish the prevalence of lithium treatment in the two regions,
all psychiatric clinics and private psychiatrists were inquired in
writing about data on their lithium-treated patients, including sex,
age, psychiatric diagnosis, serum lithium, and plasma creatinine
levels. A cutoff limit of plasma creatinine level 4150 mmol/l was
used to identify patients with CKD. The collection of data was
complete by May 2007.
Statistics
Conventional statistical methods were used to describe the salient
features of the study populations. We calculated age-standardized
prevalence by indirect standardization with the general
population in the study as standard population. We calculated
standard morbidity rate as the ratio multiplied by 100 of observed
to expected number of ESRD in the lithium population under
the assumption of identical prevalence of ESRD between the
lithium population and the general population. For the calculation
of the 95% confidence interval, we used a web-based
calculator,24 choosing the Mid-P exact test.
Ethics
The study was approved by the Regional Ethical Review Board in
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accordance with the Declaration of Helsinki.
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